Prediagnosis epilepsy and survival in patients with glioma: a nationwide population-based cohort study from 2009 to 2018

Marku, Mirketa; Rasmussen, Birthe Krogh; Belmonte, F.; Hansen, Steinbjørn; Johansen, Christoffer; Bidstrup, Pernille Envold

doi:10.1007/s00415-021-10668-6

Cited by 12 publications

(9 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the remaining 221 patients with diffuse gliomas, 54 patients did not have epilepsy. Eight patients had used ASMs indications including prophylactic medication [1] , psychiatric disease [2] , migraine [1] , and temporary use due to suspected seizure episode not receiving diagnosis of epilepsy [4] .…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Glioma features and seizure control during long-term follow-up

Ollila

Roivainen

2023

Epilepsy & Behavior Reports

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

“…Epilepsy preceding glioma diagnosis <1 year is a favorable prognostic factor in grade 2–4 diffuse glioma [2] . Recurrence or worsening of seizures may be a sign of tumor progression [3] .…”

Section: Introductionmentioning

confidence: 99%

Glioma features and seizure control during long-term follow-up

Ollila

Roivainen

2023

Epilepsy & Behavior Reports

View full text Add to dashboard Cite

“…Previous evidence indicates that epilepsy in glioma improves the survival of patients with glioma [63][64][65], which prompted us to further investigate whether miR-9-5p can be a crucial factor in this interesting phenomenon. There may be a connection between epilepsy and tumors.…”

Section: Discussionmentioning

confidence: 99%

“…Based on the results that high expression of hsa-miR-9-5p predicted longer survival in GBM and LGG, and with previous evidence indicating that the gliomainduced epilepsy may be associated with favorable prognosis [63][64][65], we hypothesized that hsa-miR-9-5p might play a key role in glioma-induced epilepsy. The gene expression profile dataset GSE32534 was used to identify DEGs between epilepsy and non-epilepsy patients with low-grade brain tumor, which were considered as risk genes (Fig.…”

Section: Hsa-mir-9-5p May Play a Critical Role In Glioma-induced Epil...mentioning

confidence: 95%

Potentials of miR-9-5p in promoting epileptic seizure and improving survival of glioma patients

Wang

Bao

et al. 2022

Acta Epileptologica

View full text Add to dashboard Cite

Background Epilepsy affects over 70 million people worldwide; however, the underlying mechanisms remain unclear. MicroRNAs (miRNAs) have essential functions in epilepsy. miRNA-9, a brain-specific/enriched miRNA, plays a role in various nervous system diseases and tumors, but whether miRNA-9 is involved in epilepsy and glioma-associated epilepsy remains unknown. Therefore, we aimed to explore the potential role of miR-9-5p in seizures and its effect on the survival of glioma patients, in order to provide new targets for the treatment of epilepsy and glioma. Methods The YM500v2 database was used to validate the expression of hsa-miR-9-5p in tissues. Moreover, qRT-PCR was performed to investigate the expression of miR-9-5p in temporal lobe epilepsy patients and rats with lithium-pilocarpine-induced seizures. Recombinant adeno-associated virus containing miR-9-5p was constructed to overexpress miR-9-5p in vivo. The effects of miR-9-5p on the behavior and electroencephalographic activities of the lithium-pilocarpine rat model of epilepsy were tested. Bioinformatics analysis was used to predict the targets of miR-9-5p and explore its potential role in epilepsy and glioma-associated epilepsy. Results The expression of miR-9-5p increased at 6 h and 7 days after lithium-pilocarpine-induced seizures in rats. Overexpression of miR-9-5p significantly shortened the latency of seizures and increased seizure intensity at 10 min and 20 min after administration of pilocarpine (P < 0.05). Predicted targets of miR-9-5p were abundant and enriched in the brain, and affected various pathways related to epilepsy and tumor. Survival analysis revealed that overexpression of miR-9-5p significantly improved the survival of patients from with low-grade gliomas and glioblastomas. The involvement of miR-9-5p in the glioma-associated epileptic seizures and the improvement of glioma survival may be related to multiple pathways, including the Rho GTPases and hub genes included SH3PXD2B, ARF6, and ANK2. Conclusions miR-9-5p may play a key role in promoting epileptic seizures and improving glioma survival, probably through multiple pathways, including GTPases of the Rho family and hub genes including SH3PXD2B, ARF6 and ANK2. Understanding the roles of miR-9-5p in epilepsy and glioma and the underlying mechanisms may provide a theoretical basis for the diagnosis and treatment of patients with epilepsy and glioma.

show abstract

“…Consistent with our ndings, Yang and Gao et al found that the expression of SLC12A5 in patients with shorter survival time was signi cantly lower than that in patients with longer survival time [39] . Paradoxically, epilepsy has been reported in some studies as an independent bene cial factor for glioma prognosis [40] . On the one hand, this nding may be due to the fact that epilepsy is thought to be associated with IDH1 mutations in low-grade gliomas [41] , and IDH mutations are associated with better glioma prognosis.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Estimation Model for Oligodendroglioma: An mRNA-Sequence Data-Based Analysis

Zhu

Shen

Yang

et al. 2022

Preprint

View full text Add to dashboard Cite

Object: In contrast with the previous diagnostic strategy, which relied only on histopathologic evidence, the integrated diagnosis of oligodendroglioma based on the 5th edition of World Health Organization Classification of Tumors of the Central Nervous System (WHO CNS 5) criteria requires the codeletion of chromosome arms 1p and 19q and isocitrate dehydrogenase gene (IDH1 or IDH2) mutation (mt). The existing prognostic indicators may not be completely suitable for oligodendroglioma patients based on the new diagnostic criteria. We aimed to identify a prognostic prediction model for oligodendrogliomas based on the WHO CNS5 classification.Methods: We collected 175 glioma samples to investigate significant changes in mRNAs using the Chinese Glioma Genome Atlas (CGGA) database and to establish a prediction model for prognosis by Least Absolute Shrinkage and Selection Operator (LASSO) and Cox logistic analysis.Results: Eighty-eight differentially expressed RNAs (DERNAs) were identified between the long survival group and the short survival group. Seven RNAs were selected to calculate risk scores. Risk level, age and Primary-or-Recurrent Status (PRS) type were used as factors for the prognostic model.Conclusion: An individualized prognostic model for oligodendroglioma patients based on the WHO CNS5 criteria was established. The predictive ability of this model was validated in a validation cohort, which demonstrated its predictive accuracy. In the future, more pathological evidence is needed to support our predictive model to further classify oligodendrogliomas.

show abstract

Prediagnosis epilepsy and survival in patients with glioma: a nationwide population-based cohort study from 2009 to 2018

Cited by 12 publications

References 48 publications

Glioma features and seizure control during long-term follow-up

Glioma features and seizure control during long-term follow-up

Potentials of miR-9-5p in promoting epileptic seizure and improving survival of glioma patients

Prognostic Estimation Model for Oligodendroglioma: An mRNA-Sequence Data-Based Analysis

Contact Info

Product

Resources

About